DAT-2645

DAT-2645 is a small molecule (oral tablet) from Danatlas Pharmaceuticals. An oral PARG inhibitor for tumours with BRCA1/2 loss of function or other DNA damage repair defects. Its furthest stage is phase 2, for solid tumours with BRCA1/2 or DNA damage repair defects and BRCA-mutated or HRD-positive ovarian cancer. ClinicalTrials.gov registers it in 2 studies linked below. Phase 1 NCT06614751 and phase 2 NCT07652073 both not yet recruiting (registry, 3 Nov 2026). Whether it works in people has not been established unless a trial below reports it.